Company milestones and innovation updates.

2026

Platform

PreditX® registered as EU trademark

Pharmaeconomica registered PreditX® as a European Union trademark, supporting the platform’s development as a distinct AI-enabled drug discovery asset within the Pharmaeconomica innovation portfolio.

2026

Scientific recognition

CSO recognized among SciRank Global’s Top 5% Scientists

Muhammad Usman Mirza, PhD, Co-founder and CSO of Pharmaeconomica, was recognized among SciRank Global’s Top 5% Scientists, reflecting his scientific contribution in computational chemistry and AI-driven discovery.

April 2026

Project milestone

Pharmaeconomica completes VLAIO feasibility project for PreditX® generative AI expansion

Pharmaeconomica completed its VLAIO feasibility project focused on assessing the practical integration of automated generative AI for de novo molecular design into PreditX®. The project strengthens the platform roadmap by clarifying key scientific, technical, and implementation considerations for the future generative AI module.

2026

Collaboration

Pharmaeconomica signs collaboration agreement with CIDEM Cuba for neurology discovery programs

Pharmaeconomica established a collaboration agreement with CIDEM in Cuba to support discovery programs in neurology. The collaboration reflects Pharmaeconomica’s strategy to combine AI-enabled discovery, computational modeling, and institutional scientific partnerships around high-need neurological conditions.

2026

Platform

PreditX® ADMET layer goes live

Pharmaeconomica expanded PreditX® with an ADMET layer to support early developability assessment. This capability strengthens the platform’s role in candidate prioritization by helping users evaluate predicted pharmacokinetic, toxicity, and developability-related risks earlier in the discovery process.

October 2025

Innovation funding

Pharmaeconomica awarded VLAIO feasibility grant for generative AI molecular design

Pharmaeconomica was awarded a VLAIO feasibility grant for the project “Feasibility study for the integration of an automated GEN AI for de novo molecular design.” The project supports the evaluation of scientific, technical, and operational requirements for integrating generative AI capabilities into the PreditX® platform.

2025

Discovery program

Pharmaeconomica identifies two selective BChE inhibitor lead compounds

Pharmaeconomica identified two lead compounds, PE01 and PE02, with strong inhibition activity against human butyrylcholinesterase (BChE) and low inhibition of acetylcholinesterase (AChE). The results support further evaluation of these compounds as part of Pharmaeconomica’s Alzheimer’s disease discovery program.

2025

Platform

PreditX® predictive module goes live

Pharmaeconomica launched the predictive module of PreditX®, enabling target-based predictive screening and small-molecule candidate prioritization. This milestone marked the transition of PreditX® from development concept to a functional AI-enabled discovery platform.

2024

Collaboration

Pharmaeconomica and FOIT&CS at UCP establish collaboration around AI-enabled drug discovery

Pharmaeconomica and the Faculty of Information Technology and Computer Science at the University of Central Punjab established a collaboration focused on AI, machine learning, and advanced computational chemistry for drug discovery research.